Research programme: neoantigen-based cancer immunotherapeutics - Gritstone Oncology/Immune Design

Drug Profile

Research programme: neoantigen-based cancer immunotherapeutics - Gritstone Oncology/Immune Design

Alternative Names: multi-genome ZVex; ZVex-Neo; ZVexMulti

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gritstone Oncology; Immune Design
  • Developer Gritstone Oncology
  • Class Antineoplastics; Cancer vaccines; Immunoproteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gastric cancer; Non-small cell lung cancer

Most Recent Events

  • 07 Sep 2017 Preclinical trials in Gastric cancer in USA (Parenteral)
  • 07 Sep 2017 Gritstone Oncology plans to advance its neoantigen-based cancer immunotherapy programme into clinical development for Non-small cell lung cancer and gastric cancer, in mid-2018
  • 11 Nov 2016 Preclinical trials in Non-small cell lung cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top